⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago
🛡️ EUSW
🇬🇧
💊

Mycamine

micafungin
Candidiasis
✅ Authorised
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Mycamine is indicated for: Adults, adolescents ≥ 16 years of age and elderly treatment of invasive candidiasis; treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate; prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days. Children (including neonates) and adolescents < 16 years of age treatment of invasive candidiasis. prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days. The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate.

⚠️ Patient safety

No

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.